A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Athanasios Dimopoulos Ivan Špička Liana Gercheva Tadeusz Robak Robert Z Orlowski Tamás Masszi |
| Publication date | January 1, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |